Veozah (Fezolinetant) and Alcohol: What Women Actually Need to Know

Does Alcohol Interact Directly with Veozah?

The FDA prescribing information for fezolinetant does not list alcohol as a pharmacokinetic drug interaction. No dedicated alcohol-drug interaction study has been published in the peer-reviewed literature as of early 2025. That data gap matters, and you deserve to know it exists rather than receiving false reassurance.

What we do know: fezolinetant is metabolized primarily by CYP1A2. Alcohol can modestly induce CYP1A2 at chronic intake levels, which could theoretically lower fezolinetant plasma concentrations slightly, but this remains speculative and has not been measured in a clinical study. Acute alcohol ingestion has a different and variable effect on CYP1A2 compared to chronic use, adding further uncertainty.

The practical takeaway: the absence of a listed interaction is not the same as a confirmed safe combination. It means the interaction simply has not been formally studied in a controlled trial.

Why This Data Gap Exists

Women have historically been under-represented in pharmacokinetic sub-studies and drug-alcohol interaction trials. The SKYLIGHT 1 and SKYLIGHT 2 phase 3 trials, which formed the basis for Veozah's FDA approval in May 2023, enrolled postmenopausal women but did not systematically characterize alcohol use or measure fezolinetant levels in drinkers versus non-drinkers. This is a gap in the evidence, not a green light.

What the Prescribing Information Does Say

The Veozah FDA prescribing information flags CYP1A2 inhibitors (such as fluvoxamine and ciprofloxacin) as drugs that can significantly raise fezolinetant exposure, and CYP1A2 inducers (such as tobacco smoke) as agents that can lower it. Alcohol sits somewhere in between depending on dose and chronicity, and that ambiguity is exactly why a frank conversation with your prescriber matters before you decide whether to drink at all.

Alcohol Is a Known Hot-Flash Trigger

This is where the real-world clinical picture becomes clearer. Even if Veozah itself has no confirmed pharmacokinetic clash with alcohol, alcohol acts on vasomotor symptoms through its own biological pathways, and that matters enormously for a drug you are taking specifically to reduce those symptoms.

Alcohol causes peripheral vasodilation and raises skin temperature. It disrupts thermoregulatory signaling in the hypothalamus, which is exactly the region where fezolinetant works by blocking NK3 receptors and reducing KNDy neuron firing. Drinking can therefore undo, or at least blunt, the benefit you are getting from your daily Veozah tablet.

A study published in Menopause found that alcohol consumption was associated with a higher frequency of vasomotor symptoms in menopausal women. The Menopause Society (formerly NAMS) identifies alcohol as one of the most commonly reported lifestyle triggers for hot flashes and night sweats. Patient-reported data consistently place alcohol among the top three modifiable triggers, alongside spicy foods and caffeine.

How Much Alcohol Is Enough to Trigger Symptoms?

For many women, even one standard drink (14 g of ethanol, the amount in a 5-oz glass of wine or 12-oz regular beer) can trigger a flash within 30 to 60 minutes. The threshold is highly individual. Women who are further into menopause, have more severe baseline symptoms, and have lower body weight tend to be more sensitive.

A practical framework for women on Veozah who want to drink occasionally:

• Track before you change anything. Use a hot-flash diary for two weeks, noting the time, number, and severity of flashes alongside when and how much you drink. This gives you your personal trigger data rather than population averages.
• Time your drink strategically. If you do drink, midday with food may blunt the vasodilation spike compared to an evening glass on an empty stomach.
• Start with a half-drink. Half a standard drink is 7 g of ethanol and may stay below your personal trigger threshold while still allowing you to participate socially.
• Note night-sweat impact separately. Alcohol consumed within three hours of bedtime is especially likely to disrupt sleep architecture and worsen night sweats, even if daytime flash frequency stays the same.

The Liver Question: Why Veozah Requires Monitoring and Alcohol Adds Risk

Liver safety is the most clinically significant reason to think carefully about alcohol while on Veozah. This is not a theoretical concern.

During the SKYLIGHT 4 long-term safety trial, fezolinetant was associated with liver enzyme elevations in a small proportion of participants. As a direct result, the FDA-approved prescribing information requires liver function testing at baseline and at 3, 6, and 9 months after starting treatment. If ALT or AST rises to more than three times the upper limit of normal, Veozah must be discontinued.

This is not a rare, buried footnote. The FDA label states plainly that fezolinetant can cause hepatocellular injury, and that women with pre-existing liver disease should not use the drug.

What Alcohol Does to the Liver Independently

Alcohol is independently hepatotoxic. Even moderate drinking (defined by the CDC as up to one drink per day for women) causes some measurable oxidative stress in hepatocytes. Heavy drinking, defined as more than seven drinks per week or more than three drinks on any single day for women, significantly raises ALT and AST and increases the risk of alcoholic fatty liver disease.

When you combine a drug that requires liver enzyme monitoring with a substance that independently raises liver enzymes, you risk making it harder to interpret your monitoring results. A mild ALT elevation at your 3-month check could reflect early fezolinetant-related hepatocellular injury, alcohol effect, or both. Your clinician needs to know your drinking habits to make that distinction safely.

The Practical Liver-Safety Rule

If you drink more than seven drinks per week on a regular basis, that is a frank contraindication to Veozah based on the liver-disease exclusion in its labeling. For women who drink occasionally (one to three drinks per week), the added liver burden is likely small, but tell your prescribing clinician your actual intake so they can weigh it against your baseline liver function tests before starting the drug.

Living with Veozah Day to Day: What Changes and What Does Not

Beyond alcohol, women ask practical questions about what daily life looks like on Veozah. Here is an evidence-anchored picture.

How Quickly Does It Work?

In SKYLIGHT 1, women taking fezolinetant 45 mg once daily saw a statistically significant reduction in moderate-to-severe hot flash frequency by week 4, with continued improvement through week 12. The mean reduction in daily hot flashes was approximately 3.5 fewer flashes per day compared to placebo at 12 weeks. That is a meaningful improvement in quality of life, but it is not instant. Give it four weeks before concluding it is not working.

Timing and Food

Veozah can be taken with or without food. The prescribing information does not restrict timing relative to meals. Taking it at the same time each day reduces the chance of missed doses and may help with consistency of plasma levels.

What Side Effects Are Most Common for Women?

In SKYLIGHT 1 and SKYLIGHT 2, the most commonly reported adverse effects were abdominal pain and diarrhea, each occurring in roughly 8 to 11% of the fezolinetant group versus 4 to 6% in placebo. These tended to be mild and did not cause high rates of discontinuation. Headache was also reported more frequently than placebo.

Night sweats improving before daytime flashes is a pattern some women notice. Sleep quality often improves first, which makes sense given that the hypothalamic NK3 pathway is active during sleep as well as daytime thermoregulatory events.

Can You Take It with Other Medications?

The biggest drug interaction concern for Veozah is strong CYP1A2 inhibitors. Fluvoxamine (Luvox), a psychiatric medication sometimes used for OCD and anxiety, is contraindicated with fezolinetant because it raises fezolinetant exposure dramatically. Ciprofloxacin is another CYP1A2 inhibitor to flag for your prescriber if you need an antibiotic.

Tobacco smoking induces CYP1A2 and could reduce fezolinetant efficacy, though this has not been quantified in a dedicated study.

Pregnancy, Lactation, and Contraception

Veozah is not indicated in premenopausal women for vasomotor symptoms and must not be used during pregnancy. This section applies to any woman who might conceive while taking the drug, including women in perimenopause who still have menstrual cycles.

Pregnancy

The FDA prescribing information states that fezolinetant should be discontinued if pregnancy is confirmed. Animal reproduction studies showed adverse developmental effects at doses higher than the human therapeutic dose, though the relevance to human pregnancy is not fully characterized. No adequate well-controlled human pregnancy studies exist. Given that the drug acts on the hypothalamic neurokinin-3 pathway, which plays a role in reproductive neuroendocrine regulation, the theoretical concern is sufficient to make avoidance during pregnancy the clear recommendation.

Women in perimenopause who are sexually active and not using contraception should discuss pregnancy risk with their clinician before starting Veozah, because perimenopause does not equal infertility. ACOG guidelines note that contraception is recommended until 12 months of amenorrhea in women under 50.

Lactation

No data exist on fezolinetant transfer into human breast milk, infant exposure, or effects on milk production. The prescribing information recommends against use during breastfeeding. Because Veozah's indication is menopausal vasomotor symptoms, use during lactation would be an off-label application. The risk-benefit calculation in a breastfeeding woman would be highly unfavorable.

Contraception Requirement

Women of reproductive potential taking Veozah should use effective contraception. This applies specifically to perimenopausal women who have not yet reached 12 months of consecutive amenorrhea. Methods with high reliability (IUD, implant, oral contraceptive pill, or barrier plus spermicide) are preferable during fezolinetant treatment.

Who Is a Good Candidate for Veozah and Who Is Not

Women Most Likely to Benefit

• Postmenopausal women with moderate-to-severe hot flashes who cannot or prefer not to use hormone therapy
• Perimenopausal women with vasomotor symptoms and a contraindication to estrogen (history of hormone-receptor positive breast cancer, personal preference against hormonal treatment, active venous thromboembolism)
• Women whose hot flashes are disrupting sleep or work functioning and who have normal baseline liver enzymes
• Women who have tried lifestyle modifications (reducing alcohol, caffeine, and spicy foods; using cooling strategies) but need pharmacologic support

The Menopause Society 2023 position statement on non-hormonal therapies identifies fezolinetant as one of the recommended non-hormonal options for women with moderate-to-severe vasomotor symptoms, placing it alongside SSRIs, SNRIs, and gabapentin.

Women Who Should Not Use Veozah

• Women with known liver disease or chronic heavy alcohol use
• Women who are pregnant or breastfeeding
• Women currently taking fluvoxamine or other strong CYP1A2 inhibitors
• Women with Child-Pugh B or C hepatic impairment

Life Stage Differences: Perimenopause Versus Postmenopause

Perimenopause

In perimenopause, vasomotor symptoms often fluctuate with the irregular hormonal swings of still-occurring cycles. Fezolinetant has not been specifically studied as a primary endpoint drug in perimenopausal women (the SKYLIGHT trials enrolled postmenopausal women), so its efficacy in the context of fluctuating estrogen levels is extrapolated rather than directly proven. ACOG recommends treatment of vasomotor symptoms based on symptom severity regardless of strict menopausal status, but the evidence base for fezolinetant is stronger in the postmenopausal population.

Alcohol's effect on hot flashes may also be more variable in perimenopause because circulating estrogen levels change week to week, altering hypothalamic sensitivity and the background "thermoneutral zone" width that governs flash threshold.

Postmenopause

The evidence for fezolinetant is strongest here. Both SKYLIGHT 1 and SKYLIGHT 2 enrolled postmenopausal women and demonstrated statistically and clinically meaningful reductions in hot flash frequency and severity at 12 weeks. The SKYLIGHT 4 trial extended safety data to 52 weeks in a similar population.

Postmenopausal women often have reduced alcohol tolerance compared to their younger selves, independent of any drug effect, because lower estrogen alters hepatic alcohol dehydrogenase activity. This means a glass of wine that caused no symptoms at age 42 may trigger a flash and disrupt sleep at age 54, even before accounting for Veozah.

Practical Guidance for Women Who Drink Occasionally

The goal is not prohibition. The goal is giving you enough information to make your own decision, adjusted for your symptom burden, your drinking habits, and your liver health.

A reasonable, evidence-informed approach for women taking Veozah who drink occasionally:

1. Keep weekly alcohol intake at or below seven standard drinks total, which is the CDC's definition of the threshold beyond which liver risk rises meaningfully for women.
2. Tell your clinician your accurate weekly average before your baseline liver function test, not after.
3. Keep a two-week hot-flash and alcohol diary to identify your personal trigger threshold.
4. Avoid alcohol within three hours of bedtime to protect sleep architecture and reduce night sweats.
5. If your 3-month liver function tests show any elevation, report your alcohol intake honestly so your clinician can interpret the result correctly.

The clinical bottom line: alcohol and Veozah do not have a documented pharmacokinetic interaction, but alcohol undermines the very symptoms Veozah is treating, and both substances place demands on the liver. Occasional moderate drinking is likely compatible with Veozah use in women with healthy livers, but heavy or regular drinking is not.